Bottom line
FHLC vs HGHAX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and HGHAX (The Hartford Healthcare Fund) share a meaningful slice of their top holdings — about 72% by weight.
But FHLC is far broader, holding 337 positions to 80 for HGHAX, so beyond the top names it adds exposure HGHAX doesn't have.
FHLC is cheaper at 0.084% vs 1.33% — a difference of $125 a year per $10,000 invested.
HGHAX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
FHLC vs HGHAX side by side
| FHLC | HGHAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Hartford |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 1.33% |
| Annual cost per $10k | $8.4 | $133 |
| 10-yr cost on $10k (prospectus) | $108 | $2,063 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +2.6% | — |
| 5-yr return (annualized) | +7.2% | — |
| 10-yr return (annualized) | +8.8% | — |
| Best quarter | +16.4% | +20.9% |
| Worst quarter | −13.1% | −15.7% |
| Net assets (fund) | $3.3B | $772.2M |
| Number of holdings | 337 | 80 |
| Portfolio turnover | 3% | 49% |
| Returns as of | Nov 30, 2025 | — |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | HGHAX | Difference |
|---|---|---|---|
| 2024 | +2.6% | 0.0% | +2.6% |
| 2023 | +2.5% | +3.8% | −1.3% |
| 2022 | −5.5% | −11.7% | +6.3% |
| 2021 | +20.4% | +10.0% | +10.4% |
| 2020 | +18.1% | +22.6% | −4.5% |
| 2019 | +21.9% | +33.3% | −11.3% |
| 2018 | +5.5% | −3.0% | +8.5% |
| 2017 | +23.3% | +21.6% | +1.7% |
| 2016 | −3.3% | −8.6% | +5.2% |
Source: Fund prospectus bar charts
Holdings overlap
19 of FHLC's top 25 holdings also appear in HGHAX's top 25.
| Holding | FHLC | HGHAX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 12.03% |
| Johnson & Johnson | 8.93% | 6.75% |
| AbbVie Inc | 6.42% | 4.21% |
| UnitedHealth Group Inc | 5.44% | 4.74% |
| Merck & Co Inc | 4.66% | 6.00% |
| Thermo Fisher Scientific Inc | 3.09% | 1.58% |
| Amgen Inc | 3.00% | 1.39% |
| Abbott Laboratories | 2.66% | 1.82% |
| CVS Health Corp | 1.92% | 2.84% |
| Intuitive Surgical Inc | 1.82% | 2.88% |
| Danaher Corp | 1.80% | 2.57% |
| Vertex Pharmaceuticals Inc | 1.76% | 2.64% |
| Stryker Corp | 1.62% | 1.24% |
| Medtronic PLC | 1.59% | 1.12% |
| Elevance Health Inc | 1.19% | 3.00% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
HGHAX top 10
- Eli Lilly & Co — 12.03%
- Johnson & Johnson — 6.75%
- Merck & Co Inc — 6.00%
- UnitedHealth Group Inc — 4.74%
- AbbVie Inc — 4.21%
- Elevance Health Inc — 3.00%
- Intuitive Surgical Inc — 2.88%
- CVS Health Corp — 2.84%
- Vertex Pharmaceuticals Inc — 2.64%
- Danaher Corp — 2.57%
FAQ
What is the difference between FHLC and HGHAX?
Which is cheaper, FHLC or HGHAX?
Should I own both FHLC and HGHAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.